Drug Approval | June 14, 2024
Farxiga approved in the US for the treatment of paediatric type-2 diabetes
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
The brand has also unveiled a new TVC campaign in Telangana and Andhra Pradesh to drive brand awareness
Highly effective preservation solutions ensuring the safety and protection of personal care products
The launch will enable PCC to further expand their existing Zinc Sulfate Injection product line and overall the generic injectables portfolio
STABILIZE-CKD and DIALIZE-Outcomes trials are part of the CRYSTALIZE evidence programme
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
The Product will be manufactured at the company's facility in Bengaluru
Lupin has been exclusively marketing these brands in the Indian market since July 2021
Subscribe To Our Newsletter & Stay Updated
